Evaluating the Long-Term Impact of MSC Therapy in Severe COVID-19 Patients
A three-year follow-up of a randomized, double-blind, placebo-controlled trial suggests that mesenchymal stem cell (MSC) therapy remains safe in severe COVID-19 patients and may contribute to improved lung recovery and quality of life.
